17-Apr-2019 - MorphoSys AG

MorphoSys received a milestone payment from Janssen

Janssen has Expanded Clinical Development of Guselkumab into Familial Adenomatous Polyposis

MorphoSys AG announced that its licensee Janssen Research & Development, LLC, has further expanded the clinical development of guselkumab (Tremfya(R)) into familial adenomatous polyposis (FAP), a disease of the gastrointestinal tract.

Janssen has initiated a phase 1b proof-of-concept clinical trial of guselkumab in patients with FAP, a dominantly inherited disorder characterized by the early onset of polyps throughout the colon which may develop into colon cancer, if not treated. This randomized study will evaluate the efficacy and safety of guselkumab vs. placebo in approximately 72 patients with FAP.

In connection with the start of clinicial development in FAP, MorphoSys received a milestone payment from Janssen. Financial details were not disclosed.

Guselkumab is a human anti-IL-23 monoclonal antibody developed by Janssen that was generated utilizing MorphoSys's proprietary HuCAL antibody technology.

Dr. Markus Enzelberger, Chief Scientific Officer of MorphoSys AG, said: "We are very pleased that our licensee Janssen has further expanded the clinical development program of guselkumab by initiating the clinical study in familial adenomatous polyposis. We see a high medical need to investigate new treatment options for patients suffering from this serious inflammatory disease of the gastrointestinal tract which, if not treated, may develop into colon cancer."

Guselkumab (tradename Tremfya(R)) has been approved in the U.S., Canada, the European Union, and several other countries for the treatment of plaque psoriasis and in Japan for the treatment of various forms of psoriasis, psoriatic arthritis, and palmoplantar pustulosis. Guselkumab is currently being investigated in clinical studies in several indications, including additional studies in plaque psoriasis, pediatric psoriasis, psoriatic arthritis, Crohn's disease, hidradenitis suppurativa, ulcerative colitis and now familial adenomatous polyposis. MorphoSys is eligible to certain milestone payments and receives royalties on net sales of Tremfya(R).

Facts, background information, dossiers
More about MorphoSys
  • News

    MorphoSys and Vivoryon Therapeutics Enter Agreement in Immuno-Oncology

    MorphoSys AG and Vivoryon Therapeutics AG announced that they have entered into an agreement under the terms of which MorphoSys has obtained an exclusive option to license Vivoryon's small molecule QPCTL inhibitors in the field of oncology. The option covers worldwide development and commer ... more

    MorphoSys Appoints Jean-Paul Kress as New CEO

    MorphoSys AG announced that its Supervisory Board has appointed Jean-Paul Kress, M.D., as its new Chief Executive Officer (CEO). The appointment will take effect on September 1, 2019. Dr. Kress brings over 20 years of experience in the pharmaceutical and biotechnology industry, with a stron ... more

    Galapagos and MorphoSys announce start of a Phase 1 subcutaneous bridging study with MOR106

    Galapagos NV and MorphoSys AG announced the initiation of a Phase 1 bridging study testing a subcutaneous formulation of MOR106, an investigational antibody directed against IL-17C. This bridging study is a parallel-design Phase 1 clinical trial conducted in two parts. Part 1 is a single ce ... more

  • Job Offers

    Clinical Trial Manager (gn)

    We would like to fill the following vacancy as soon as possible: Contributes to planning of global clinical trials and designs site management processes from study start-up to closure in collaboration with global CRO(s) and sponsor Clinical Trial Team (CTT) meeting the requirements of the ... more

  • Companies

    MorphoSys AG

    MorphoSys AG, located in Martinsried/Munich, is one of the worlds leading biotechnology companies focusing on fully human antibodies. With its unique technologies, MorphoSys is developing the next generation of therapeutic antibodies which can be used not only for research and diagnostics b ... more